Paushak Limited – Fundamental Analysis

by

Deep Fundamental Analysis: Paushak Limited

Current Data Date: 27 January 2026 (Today) Current Market Price (CMP): ₹531 – ₹535 (Live Update: Stock up ~1.1% post-results)

⚠️ CRITICAL UPDATE: Q3 FY26 RESULTS (ANNOUNCED TODAY)

Special Note: Paushak Limited ne aaj hi (27 January 2026) apne Q3 FY26 ke natije ghoshit kiye hain.

  • The Headline: Weak Profitability. Revenue flat raha hai lekin Profit me badi girawat aayi hai.
  • Revenue: ₹48.80 Crore (Down -0.9% YoY). Sales stagnant hain.
  • Net Profit: ₹6.17 Crore (Down -59.6% YoY). Profit aadhe se bhi kam ho gaya hai.
  • The Reason: Profit girne ka mukhya karan “Employee Costs” me badhotri (New Labour Codes provision ~₹1 Cr) aur “Other Income” ka kam hona hai.
  • Market Reaction: Profit girne ke bawajood stock Hara Nishaan (Green) me band hua (+1.1%). Iska karan hai New Plant Commissioning (Future Growth) ki news jo market ko support kar rahi hai.

1️⃣ Business Model & Work

  • Core Business: Paushak India ki sabse badi “Phosgene-based Specialty Chemicals” manufacturer hai. Ye Alembic Group ka hissa hai (Established player).
  • Why Phosgene? Phosgene banana aur handle karna extremely dangerous aur regulated hai. Isliye isme competition kam hai (High Entry Barrier).
  • Key Products: Isocyanates, Chloroformates, Carbamoyl Chlorides. Ye Pharma (API intermediates), Agrochemicals, aur Performance Chemicals me use hote hain.
  • Strategic Moat: Inka integrated facility Vadodara me hai jo backward integrated hai. Ye “Hazardous Chemistry” ke expert hain.

2️⃣ Industry & Sector Analysis

  • Sector Status: Specialty Chemicals (Consolidation Phase).
  • China+1: Global pharma companies China se hatkar India se sourcing badha rahi hain. Paushak, jo ki ek matra bada independent Phosgene player hai, iska beneficiary hai.
  • Cost Pressure: Chemical sector abhi “Low Demand” aur “High Input Cost” ke cycle se guzar raha hai, jiska asar Paushak ke margins par dikh raha hai.

3️⃣ Latest Financial Performance (STRICT DATA RULE)

Data Source: Q3 FY26 Results (Announced 27 Jan 2026)

Metric (Standalone)Q3 FY26 (Dec ’25)Q3 FY25 (Dec ’24)Trend
Revenue₹48.80 Cr₹49.26 Cr➡️ Flat (-0.9%)
Net Profit (PAT)₹6.17 Cr₹15.26 Cr↘️ -59.6% (Sharp Fall)
EPS (Quarterly)₹2.50₹6.19↘️ Compressed
9-Month Revenue₹163.46 Cr₹158.59 Cr↗️ +3.1% (YTD Growth)
9-Month Profit₹26.82 Cr₹39.77 Cr↘️ -32.6%
  • CRITICAL ANALYSIS OF Q3:
    • Operational De-leverage: Revenue flat hone ke bawajood fixed costs (Employee/Power) badhe hain, jisne margins ko crush kar diya.
    • One-time Hit: Government ke naye Labour Codes ke chalte company ne provisions banaye hain, jo is quarter ke profit ko kha gaye.
    • Silver Lining: Revenue growth bhale hi na ho, lekin Volumes stable hain. Pricing pressure ke karan value growth nahi dikh rahi.

4️⃣ Corporate Action & Expansion (The Game Changer)

  • New Plant Live (Jan 21, 2026): Company ne 6 din pehle hi announce kiya ki unka naya ₹175 Crore ka Multi-purpose Plant commercial production shuru kar chuka hai.
    • Impact: Ye plant company ki capacity ko significantly badhayega. Iska revenue impact Q4 FY26 aur FY27 se dikhna shuru hoga.
  • Bonus Issue (3:1): October 2025 me company ne har 1 share par 3 naye share bonus diye the. Is wajah se stock price adjust hokar ₹500 ki range me hai (Adjusted from ₹2000+). Isse liquidity badhi hai.
  • NSE Listing: November 2025 me company NSE par list hui, jisse visibility improve hui hai.

5️⃣ Management & Shareholding (Latest Pattern – Dec 2025)

  • Promoters (Amin Family – Alembic Group):67.28% (Stable).
    • Trust: Alembic Group (Chirayu Amin) ka management conservative lekin shareholder-friendly mana jata hai.
  • FIIs/DIIs:Negligible (<1%).
    • Opportunity: Institutional holding ka na hona ek tarah se opportunity bhi hai. Agar naye plant se growth aati hai, to FIIs/DIIs enter kar sakte hain jo price ko re-rate karega.

6️⃣ Valuation (Latest Market Data)

  • Current Market Price (CMP): ~₹531
  • Market Cap: ~₹1,300 Cr.
  • P/E Ratio:~28x – 30x (Trailing).
    • Comparison: Atul Ltd (~30x), Vinati Organics (~35x).
    • View: Current depressed earnings par 30x PE mehenga lag sakta hai. Lekin market “Past Earnings” ko nahi, balki “Future Earnings” (New Plant) ko value kar raha hai. Agar naya plant ₹200-300 Cr revenue add karta hai, to forward PE drastically kam ho jayega.
  • Debt: Almost Zero Debt. Naya capex internal accruals se kiya gaya hai (Strong Balance Sheet).

7️⃣ Future Growth Triggers (3–5 Years)

  1. Capex Monetization: ₹175 Cr ka naya plant agle 2-3 saalo me revenue ko double karne ki kshamta rakhta hai.
  2. Product Expansion: Phosgene derivatives ka use EV batteries (Electrolytes) aur specialized polymers me badh raha hai.
  3. Entry Barrier: Naye players ke liye Phosgene license milna mushkil hai, jo Paushak ke margins ko long term me protect karega.

8️⃣ Risk & Red Flags

  • Safety Risk: Phosgene ek zahreele gas hai. Koi bhi accident (leakage) company ke liye existential threat ban sakta hai.
  • Single Location: Sari manufacturing Vadodara (Gujarat) me concentrated hai. Geographical risk high hai.
  • Client Concentration: Top clients par nirbharta zyada hai.

9️⃣ Final Verdict

  • View: ACCUMULATE FOR LONG TERM (Turnaround Bet)
  • Risk Profile: Moderate (Zero Debt) to High (Operational Safety).
  • Target: 2-3 Years View.

Summary Points:

  • ❌ Bad Quarter: Q3 results kamzor hain (Profit -60%). Short term me stock range-bound reh sakta hai.
  • ✅ Future Ready: ₹175 Cr ka naya plant abhi chalu hua hai. Asli khel ab shuru hoga.
  • ✅ Clean Balance Sheet: Bina karze ke expansion karna management ki quality dikhata hai.
  • ✅ Low Float: Promoters ke paas 67% maal hai. Public ke paas supply kam hai.
  • Strategy: Current price (₹530) par aggressive na hon. Agar market result ki wajah se ise ₹480-500 tak girata hai, to wo accumulation zone hoga. Ye stock “FY27 Earnings” ka play hai.

Leave a Comment